Relation of Serum Plasmalogens and Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study

Overview

Journal Brain Sci

Publisher MDPI

Date 2019 Apr 27

PMID 31022959

Citations 11

Authors

Dayan B Goodenowe

Vijitha Senanayake

Affiliations

Soon will be listed here.

Abstract

Using a community sample of 1205 elderly persons, we investigated the associations and potential interactions between Apolipoprotein E ( genotype and serum phosphatidylethanolamine (PlsEtn) on cognition and dementia. For each person, genotype, PlsEtn Biosynthesis value (PBV, the combination of three key PlsEtn species), cognition (the combination of five specific cognitive domains), and diagnosis of dementia was determined. genotype and PBV were observed to be non-interacting ( > 0.05) and independently associated with cognition: (relative to ε3ε3:ε2ε3 (Coef = 0·14, = 4.2 × 10); ε3ε4/ε4ε4 (Coef = -0.22, = 6.2 × 10); PBV (Coef = 0.12, = 1.7 × 10) and dementia: (relative to ε3ε3:ε2ε3 (Odds Ratio OR = 0.44, = 3.0 × 10); ε3ε4/ε4ε4 (OR = 2.1, = 2.2 × 10)); PBV (OR = 0.61, = 3.3 × 10). Associations are expressed per standard deviation (SD) and adjusted for serum lipids and demographics. Due to the independent and non-interacting nature of the and PBV associations, the prevalence of dementia in ε3ε4/ε4ε4 persons with high PBV values (>1 SD from mean) was observed to be the same as ε3ε3 persons (14.3% versus 14.0%). Similarly, the prevalence of dementia in ε3ε3 persons with high PBV values was only 5.7% versus 6.7% for ε2ε3 persons. The results of these analyses indicate that the net effect of genotype on cognition and the prevalence of dementia is dependent upon the plasmalogen status of the person.

Citing Articles

Editorial: Solving the plasmalogen puzzle-From basic science to clinical application.

Dorninger F, Berger J, Honsho M Front Cell Dev Biol. 2023; 11:1137868.

PMID: 36727111 PMC: 9885182. DOI: 10.3389/fcell.2023.1137868.

Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species.

Goodenowe D, Senanayake V Front Cell Dev Biol. 2022; 10:866156.

PMID: 36092723 PMC: 9451657. DOI: 10.3389/fcell.2022.866156.

Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons.

Goodenowe D, Haroon J, Kling M, Zielinski M, Mahdavi K, Habelhah B Front Cell Dev Biol. 2022; 10:864842.

PMID: 35874835 PMC: 9297104. DOI: 10.3389/fcell.2022.864842.

Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer's Disease.

Guan X, Iyaswamy A, Sreenivasmurthy S, Su C, Zhu Z, Liu J Int J Mol Sci. 2022; 23(7).

PMID: 35408965 PMC: 8998506. DOI: 10.3390/ijms23073609.

APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.

Wang T, Huynh K, Giles C, Mellett N, Duong T, Nguyen A Alzheimers Dement. 2022; 18(11):2151-2166.

PMID: 35077012 PMC: 9787288. DOI: 10.1002/alz.12538.

References

Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y . Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem. 1999; 45(4):497-504. View

Guan Z, Wang Y, Cairns N, Lantos P, Dallner G, SINDELAR P . Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol. 1999; 58(7):740-7. DOI: 10.1097/00005072-199907000-00008. View

Michikawa M, Fan Q, Isobe I, Yanagisawa K . Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000; 74(3):1008-16. DOI: 10.1046/j.1471-4159.2000.0741008.x. View

Knopman D, DeKosky S, Cummings J, Chui H, Corey-Bloom J, Relkin N . Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56(9):1143-53. DOI: 10.1212/wnl.56.9.1143. View

Han X, Holtzman D, McKeel Jr D . Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001; 77(4):1168-80. DOI: 10.1046/j.1471-4159.2001.00332.x. View

Bennett D, Wilson R, Schneider J, Evans D, Beckett L, Aggarwal N . Natural history of mild cognitive impairment in older persons. Neurology. 2002; 59(2):198-205. DOI: 10.1212/wnl.59.2.198. View

Munn N, Arnio E, Liu D, Zoeller R, Liscum L . Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res. 2003; 44(1):182-92. DOI: 10.1194/jlr.m200363-jlr200. View

Bennett D, Wilson R, Schneider J, Evans D, Aggarwal N, Arnold S . Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003; 60(2):246-52. DOI: 10.1212/01.wnl.0000042478.08543.f7. View

Cutler R, Kelly J, Storie K, Pedersen W, Tammara A, Hatanpaa K . Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(7):2070-5. PMC: 357053. DOI: 10.1073/pnas.0305799101. View

10.

Raber J, Huang Y, Ashford J . ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004; 25(5):641-50. DOI: 10.1016/j.neurobiolaging.2003.12.023. View

11.

Ashford J . APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci. 2004; 23(3):157-65. DOI: 10.1385/JMN:23:3:157. View

12.

Igbavboa U, Eckert G, Malo T, Studniski A, Johnson L, Yamamoto N . Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE 3 and 4 and by increasing age. J Neurol Sci. 2005; 229-230:225-32. DOI: 10.1016/j.jns.2004.11.037. View

13.

Bennett D, Schneider J, Buchman A, Mendes de Leon C, Bienias J, Wilson R . The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005; 25(4):163-75. DOI: 10.1159/000087446. View

14.

Ghribi O, Larsen B, Schrag M, Herman M . High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol. 2006; 200(2):460-7. DOI: 10.1016/j.expneurol.2006.03.019. View

15.

Bennett D, Schneider J, Aggarwal N, Arvanitakis Z, Shah R, Kelly J . Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006; 27(3):169-76. DOI: 10.1159/000096129. View

16.

Goodenowe D, Cook L, Liu J, Lu Y, Jayasinghe D, Ahiahonu P . Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res. 2007; 48(11):2485-98. DOI: 10.1194/jlr.P700023-JLR200. View

17.

Rouser G, Yamamoto A . Curvilinear regression course of human brain lipid composition changes with age. Lipids. 1968; 3(3):284-7. DOI: 10.1007/BF02531202. View

18.

Gronn M, Christensen E, Hagve T, CHRISTOPHERSEN B . Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim Biophys Acta. 1991; 1081(1):85-91. DOI: 10.1016/0005-2760(91)90254-f. View

19.

Getz G, Reardon C . Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res. 2008; 50 Suppl:S156-61. PMC: 2674757. DOI: 10.1194/jlr.R800058-JLR200. View

20.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View